Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Phillip W. Berman"'
Autor:
Jennie M. Hutchinson, Kathryn A. Mesa, David L. Alexander, Bin Yu, Sara M. O'Rourke, Kay L. Limoli, Terri Wrin, Steven G. Deeks, Phillip W. Berman
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Although it is now possible to produce recombinant HIV envelope glycoproteins (Envs) with epitopes recognized by the 5–6 major classes of broadly neutralizing antibodies (bNAbs), these have failed to consistently stimulate the formation of bNAbs in
Externí odkaz:
https://doaj.org/article/11643b47fddd46b08a75ad69e0436a9d
Autor:
Rachel C. Doran, Bin Yu, Meredith Wright, Sara M. O'Rourke, Lu Yin, Jennie M. Richardson, Gabriel Byrne, Kathryn A. Mesa, Phillip W. Berman
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
The high rate of new HIV infections, particularly in Sub-Saharan Africa, emphasizes the need for a safe and effective vaccine to prevent acquired immunodeficiency syndrome (AIDS). To date, the only HIV vaccine trial that has exhibited protective effi
Externí odkaz:
https://doaj.org/article/4b40db027d8f411d9b6642964c17c922
Autor:
Peter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, Lindsay N Carpp, Barton F Haynes, Hua-Xin Liao, David C Montefiori, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Gustavo H Kijak, Sodsai Tovanabutra, Donald P Francis, Carter Lee, Faruk Sinangil, Phillip W Berman, Nakorn Premsri, Prayura Kunasol, Robert J O'Connell, Nelson L Michael, Merlin L Robb, Rhoda Morrow, Lawrence Corey, Jerome H Kim
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0176428 (2017)
BACKGROUND:In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX® B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent AIDSVAX® B/E vaccine contains two gp120 envelope glycoproteins, one from the
Externí odkaz:
https://doaj.org/article/749ab0ed603a4682a6678cef9d673819
Autor:
Mohammed S Aiyegbo, Evgeny Shmelkov, Lorenzo Dominguez, Michael Goger, Shibani Battacharya, Allan C deCamp, Peter B Gilbert, Phillip W Berman, Timothy Cardozo
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170530 (2017)
The only evidence of vaccine-induced protection from HIV acquisition in humans was obtained in the RV144 HIV vaccine clinical trial. One immune correlate of risk in RV144 was observed to be higher titers of vaccine-induced antibodies (Abs) reacting w
Externí odkaz:
https://doaj.org/article/abd1b8611f2343b59eeba8e06791008e
Autor:
Sara M O'Rourke, Ruengpung Sutthent, Pham Phung, Kathryn A Mesa, Normand L Frigon, Briana To, Navin Horthongkham, Kay Limoli, Terri Wrin, Phillip W Berman
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119608 (2015)
Understanding the molecular determinants of sensitivity and resistance to neutralizing antibodies is critical for the development of vaccines designed to prevent HIV infection. In this study, we used a genetic approach to characterize naturally occur
Externí odkaz:
https://doaj.org/article/62c94d1f465d48b89e2132a7d1590acf
Autor:
Meredith Wright, Kathryn A. Mesa, Bin Yu, Phillip W. Berman, Gabriel Byrne, Sara M. O'Rourke, Sophia W Li
Publikováno v:
Biotechnology and Bioengineering. 116:2130-2145
Proteolysis associated with recombinant protein expression in Chinese Hamster Ovary (CHO) cells has hindered the development of biologics including HIV vaccines. When expressed in CHO cells, the recombinant HIV envelope protein, gp120, undergoes prot
Autor:
Bin Yu, Sara M. O'Rourke, Javier Morales, Christopher Vollmers, Phillip W. Berman, David L. Alexander, Chelsea Didinger
Publikováno v:
J Immunol Methods
We have developed a stable Chinese Hamster Ovary (CHO) cell line for the production of a recombinant monoclonal antibody (mAb) to a short protein sequence derived from the N-terminus of human herpes simplex virus type 1 glycoprotein D (HSV-1 gD). The
Autor:
Raphael Gottardo, Robert T Bailer, Bette T Korber, S Gnanakaran, Joshua Phillips, Xiaoying Shen, Georgia D Tomaras, Ellen Turk, Gregory Imholte, Larry Eckler, Holger Wenschuh, Johannes Zerweck, Kelli Greene, Hongmei Gao, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Merlin L Robb, Nelson L Michael, Jerome H Kim, Susan Zolla-Pazner, Barton F Haynes, John R Mascola, Steve Self, Peter Gilbert, David C Montefiori
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75665 (2013)
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope glycoproteins have potential to mediate antiviral effector functions that could be beneficial to vaccine-induced protection. Here, plasma IgG responses were assessed in
Externí odkaz:
https://doaj.org/article/df8c4ccdd54e4bd9aaaede24511613f5
Autor:
Jay A. Berzofsky, Bin Yu, David H. Margulies, Phillip W. Berman, Lisa F. Boyd, Rolf Billeskov, Blake Frey, Gwen P. Tatsuno, Shahram Solaymani-Mohammadi, Jiansheng Jiang, Yongjun Sui
Publikováno v:
The Journal of Immunology. 200:1853-1864
Unlike cytosolic processing and presentation of viral antigens by virus-infected cells, antigens first expressed in an infected non-professional antigen-presenting cell, such as CD4(+) T cells in the case of HIV, and then taken up by dendritic cells
Autor:
Marcos Pérez-Losada, David V Jobes, Faruk Sinangil, Keith A Crandall, Miguel Arenas, David Posada, Phillip W Berman
Publikováno v:
PLoS ONE, Vol 6, Iss 3, p e16902 (2011)
In 2003, a phase III placebo-controlled trial (VAX003) was completed in Bangkok, Thailand. Of the 2,546 individuals enrolled in the trial based on high risk for infection through injection drug use (IDU), we obtained clinical samples and HIV-1 sequen
Externí odkaz:
https://doaj.org/article/d64cbcc6c854469bb99cd4b7a75d19a5